Kunming Pharmaceutical Group nominates three board director candidates, and post-70s executive Huang Yuanhong is appointed as vice president.

Kunyuan Pharmaceutical Liu Zhiying On March 19, Kunyu Group (SH600422) announced that due to work adjustments, Wu Wendu has applied to resign from the positions of Director of the 11th Board of Directors, Member of the Strategy and ESG Committee, and Member of the Nomination Committee of the Board. Guo Ting has applied to resign from his position as Director of the company. After resigning, Wu Wendu and Guo Ting will no longer hold any positions in the company.

The company’s Board of Directors nominated Wang Liang, Zhong Jiang, and Deng Kang as non-independent director candidates for the 11th Board of Directors, and agreed to submit this matter to the company’s shareholders’ meeting for review. Based on the company’s development and operational management needs, and after approval at the 15th meeting of the 11th Board of Directors, the company appointed Huang Yuanhong as Vice President.

Wang Liang, male, born in 1978, holds a master’s degree in science. He previously served as Head of Market Research Department at Shenzhen Sanyou Pharmaceutical Trading Co., Ltd., Assistant General Manager of Marketing Center, Deputy General Manager of Marketing and Brand Management Department, General Manager of Strategic Operations Department, and General Manager of R&D Center at China Resources Sanyou Pharmaceutical Co., Ltd. He is currently Vice President of China Resources Sanyou Pharmaceutical Co., Ltd.

Zhong Jiang, male, born in 1975, holds an MBA. He previously served as Deputy General Manager and CFO of China Resources Yaan Pharmaceutical Co., Ltd., Assistant General Manager, Deputy General Manager, and General Manager of Financial Management Center at China Resources Sanyou Pharmaceutical Co., Ltd., and General Manager of the Audit Department. He is also Chairman of the Supervisory Board of Kunyu Group Co., Ltd. Currently, he is President of Kunyu Group Co., Ltd.

Deng Kang, male, born in 1985, holds an MBA and is an economist. He previously worked in the Shandong region of Hongta Group’s Marketing Center, Yunnan Tobacco Marketing Center’s Shandong Branch, Hongta Securities Co., Ltd.'s Investment Banking Department, Deputy Director of Operations Management at Yunnan Hehe (Group) Co., Ltd., and Supervisor of Kunyu Group Co., Ltd. He is currently Deputy Director of the Network Information Department at Yunnan Hehe (Group) Co., Ltd., and serves as director of Hongta Innovation (Qingdao) Equity Investment Management Co., Ltd. and Kunming Zhengji Real Estate Co., Ltd.

Huang Yuanhong, male, born in 1974, holds a master’s degree in engineering. He previously served as Head of Quality Management Department at Yaan Sanyou Pharmaceutical Co., Ltd., Deputy General Manager of Beijing China Resources High-Tech Natural Medicine Co., Ltd., and Vice President of Production Operations Center, General Manager of Production Technology Center, Director of the Process Technology Research Institute, Director of Deep Blue Laboratory, and General Manager of Guanlan Base at China Resources Sanyou Pharmaceutical Co., Ltd. He is currently Vice President of Kunyu Group Co., Ltd.

It is noteworthy that since the beginning of this year, senior management changes at Kunyu Group have been continuous.

On January 5, Kunyu Group announced that due to work adjustments, Wu Wendu no longer serves as Chairman of the Board, but continues as Director, Member of the Strategy and ESG Committee, and Member of the Nomination Committee. Approved at the 14th meeting of the 11th Board, non-independent director Yu Xiang was elected as Chairman of the 11th Board of Directors.

On the same day, due to work transfer, Yan Wei no longer serves as President but continues as Vice Chairman, Director, and Member of the Strategy and ESG Committee; Li Lichun no longer holds the position of Vice President. Based on the company’s development and operational needs, the Board appointed Zhong Jiang as President.

On January 7, Kunyu Group announced again that due to work adjustments, Li Hongshen applied to resign from his positions as Vice Chairman, Director, Member of the Strategy and ESG Committee, and Member of the Audit and Risk Control Committee of the 11th Board. After resignation, Li Hongshen will no longer hold any positions in the company.

Founded in March 1951, Kunyu Group was listed on the Shanghai Stock Exchange in December 2000. Its main business includes drug research and development, production and sales, pharmaceutical distribution, and the health industry. In December 2022, China Resources Sanyou completed part of Kunyu Group’s equity acquisition, becoming its largest shareholder.

By 2025, Kunyu Group’s operating revenue is approximately 6.575 billion yuan, a decrease of 21.74% year-over-year; net profit attributable to shareholders of the listed company is about 350 million yuan, down 46%; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses is 107 million yuan, a decrease of 74.45%.

Related company: Kunyu Group sh600422